Purpose: Data are lacking on long-term outcomes of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity. The aim of this study was to assess the outcomes of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity after more than 10 years of followup.

Materials And Methods: We retrospectively reviewed the charts of all consecutive neurological patients who had received onabotulinumtoxin A or abobotulinumtoxin A intradetrusor injections for neurogenic detrusor overactivity between January 2002 and November 2007 at a total of 3 academic centers. The primary outcome measure was the 10-year discontinuation rate. Other outcomes of interest were failure, reasons for discontinuation and subsequent treatments of neurogenic detrusor overactivity. Discontinuation-free and failure-free survival was estimated by Kaplan-Meier analyses.

Results: A total of 140 patients were included in study. The 10-year discontinuation-free and failure-free survival rates were 49.1% and 73%, respectively. The most common reason for discontinuation was failure in 43.7% of cases, which was primary and secondary in 17.2% and 26.5%, respectively. Secondary failure occurred after a median of 8 injections and a median of 80.1 months from the first injection. Other reasons for discontinuation were patient decision in 28.1% of patients, nonbotulinum toxin A related improvement of urinary incontinence in 14.1%, neurological condition progression in 12.5% and an adverse event in 1.6%. Discontinuation-free survival was significantly poorer in patients with spina bifida than in patients with multiple sclerosis or spinal cord injury (p = 0.02).

Conclusions: More than half of the patients with neurogenic detrusor overactivity discontinued intradetrusor botulinum toxin A within the first 10 years after the initial injection. Patients with spina bifida are at high risk for discontinuation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2018.10.012DOI Listing

Publication Analysis

Top Keywords

neurogenic detrusor
24
detrusor overactivity
24
botulinum toxin
16
intradetrusor injections
16
injections neurogenic
8
outcomes intradetrusor
8
injections botulinum
8
toxin neurogenic
8
reasons discontinuation
8
discontinuation-free failure-free
8

Similar Publications

Objectives: To assess long-term outcomes (up to 10 cycles) of repeated intradetrusor botulinum toxin (BoNT) utilisation in multiple sclerosis (MS) and idiopathic overactive bladder (OAB).

Materials And Methods: This is a retrospective, international, multi-centre, observational cohort study of patients diagnosed with MS and neurogenic OAB and treated with intradetrusor BoNT between January 2005 and January 2020 (just prior to COVID-19 interruption). Dose, efficacy, duration of effect, International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) and International Consultation on Incontinence Questionnaire Urinary Incontinence (ICIQ-UI) measures and complication rates were recorded.

View Article and Find Full Text PDF

Managing overactive bladder (OAB) in children is recommended to involve rehabilitation intervention including urotherapy, clean intermittent catheterization (CIC), and medication. However, there is scarce evidence on the management of OAB in children in Vietnam, as well as the effectiveness of combining urotherapy, CIC, and medication in managing this condition. We report a case of an 11-year-old female pediatric patient with OAB following aneurysmal bone cyst (ABC) surgery.

View Article and Find Full Text PDF

Introduction: Neurogenic bladder dysfunction is a prevalent condition characterized by impaired bladder control resulting from neurological conditions, for example, spinal cord injury or traumatic brain injury (TBI). Detrusor overactivity is a typical symptom of central nervous system damage. A lesion affecting the pontine neural network typically results in loss of tonic inhibition exerted by the pontine micturition center and causes involuntary detrusor contractions.

View Article and Find Full Text PDF

Introduction And Objective: Observable autonomous rhythmic changes in intravesical pressure, termed bladder wall micromotion, is a phenomenon that has been linked to urinary urgency, the key symptom in overactive bladder (OAB). However, the mechanism through which micromotion drives urinary urgency is poorly understood. In addition, micromotion is inherently difficult to study in human urodynamics due to challenges distinguishing it from normal cyclic physiologic processes such as pulse rate, breathing, rectal contractions, and ureteral jetting.

View Article and Find Full Text PDF

[Neurogenic lower urinary tract dysfunction following spinal cord injury].

Urologie

January 2025

Neuro-Urologie, Schweizer Paraplegiker-Zentrum, Guido A. Zäch-Straße 1, 6207, Nottwil, Schweiz.

A spinal cord injury (SCI) leads to neurogenic lower urinary tract dysfunction (NLUTD), which, if left untreated, can result not only in urinary incontinence and an increased risk of urinary tract infections and kidney dysfunction but may also pose a vital threat to people with SCI. Comprehensive neurourological assessments, including patient history and combined video urodynamics, are essential to accurately classify dysfunction and establish therapeutic strategies. Treatment options include, among others, medications for detrusor regulation, intermittent catheterization, and, if necessary, surgical interventions from intradetrusor botulinum toxin A injections to sacral deafferentation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!